多种药物耐药性蛋白-1 影响氧化应激,内皮功能障碍和通过白血C4出口的动脉生成
Cornelius F H Mueller1, Kerstin Wassmann, Julian D Widder
1Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany. cornelius.mueller@ukb.uni-bonn.de
Circulation
|May 29, 2008
概括
多重耐药性蛋白-1 (MRP1) 和白血C4 (LTC4) 通过增加血管细胞中的氧化应激来促进动脉样硬化. 抑制MRP1或LTC4受体可以减少斑块形成并改善血管功能.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 氧化压力研究研究 氧化压力研究
背景情况:
- 多重耐药性蛋白-1 (MRP1) 在血管细胞中控制氧化应激起作用.
- 在血管氧化应激中MRP1的精确机制和体内相关性仍然不清楚.
- 通过MRP1传输的Leukotriene C4 (LTC4) 运输被假设为一种益风性病原机制.
研究的目的:
- 研究MRP1和LTC4在血管氧化应激和动脉样硬化中的作用.
- 为了确定抑制MRP1或LTC4受体 (Cys-LT1) 在体外和体内是否具有甲状腺保护作用.
主要方法:
- 血管光滑肌细胞 (VSMC) 用于研究MRP1抑制 (MK571) 和Cys-LT1受体阻塞 (蒙特卢卡斯特) 对活性氧物种 (ROS) 释放的影响.
- 评估了LTC4释放及其对VSMC增殖的影响.
- 易患动脉样硬化的阿波利波蛋白E缺陷小鼠被用MRP1或Cys-LT1受体抑制剂治疗,以评估体内对血管ROS,内皮功能和动脉样硬化斑块负担的影响.
主要成果:
- 抑制MRP1 (MK571) 降低了59%的VSMC中的血管新生素II诱导的ROS释放.
- Cys-LT1受体阻塞 (蒙特卢卡斯特) 也抑制了血管素II诱导的ROS释放.
- 在小鼠中抑制MRP1或Cys-LT1受体显著降低了血管ROS产量,改善了内皮功能,并分别减少了52%和61%的动脉样硬化斑块.
结论:
- MRP1和LTC4有助于产生动脉样硬化作用.
- 向MRP1或LTC4受体是动脉动脉保护的有希望的治疗策略.
相关概念视频
Clinical Significance of Antibiotic Resistance
7
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
7
Mechanism of Antibiotic Resistance in MRSA
37
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
37
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
104
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
104
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
102
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
102
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
5.0K


